Kiromic Biopharma Performance
| KRBPDelisted Stock | USD 2.68 0.07 2.55% |
The company secures a Beta (Market Risk) of 2.23, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Kiromic Biopharma will likely underperform. Kiromic Biopharma right now secures a risk of 0.0%. Please verify Kiromic Biopharma treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Kiromic Biopharma will be following its current price movements.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Kiromic Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable fundamental drivers, Kiromic Biopharma is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 25.4 M |
Kiromic |
Kiromic Biopharma Relative Risk vs. Return Landscape
If you would invest 268.00 in Kiromic Biopharma on November 3, 2024 and sell it today you would earn a total of 0.00 from holding Kiromic Biopharma or generate 0.0% return on investment over 90 days. Kiromic Biopharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Kiromic, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Kiromic Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kiromic Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kiromic Biopharma, and traders can use it to determine the average amount a Kiromic Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| KRBP |
Based on monthly moving average Kiromic Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kiromic Biopharma by adding Kiromic Biopharma to a well-diversified portfolio.
Kiromic Biopharma Fundamentals Growth
Kiromic Stock prices reflect investors' perceptions of the future prospects and financial health of Kiromic Biopharma, and Kiromic Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kiromic Stock performance.
| Return On Equity | -11.3 | ||||
| Return On Asset | -0.92 | ||||
| Current Valuation | 9.55 M | ||||
| Shares Outstanding | 1.18 M | ||||
| Price To Book | 15.11 X | ||||
| EBITDA | (29.44 M) | ||||
| Cash And Equivalents | 6.51 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 9.41 M | ||||
| Debt To Equity | 0.20 % | ||||
| Book Value Per Share | (5.35) X | ||||
| Cash Flow From Operations | (23.75 M) | ||||
| Earnings Per Share | (39.68) X | ||||
| Total Asset | 11.97 M | ||||
| Retained Earnings | (101.95 M) | ||||
About Kiromic Biopharma Performance
Assessing Kiromic Biopharma's fundamental ratios provides investors with valuable insights into Kiromic Biopharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Kiromic Biopharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. Kiromic Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people.Things to note about Kiromic Biopharma performance evaluation
Checking the ongoing alerts about Kiromic Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kiromic Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kiromic Biopharma is not yet fully synchronised with the market data | |
| Kiromic Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (34.73 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Kiromic Biopharma currently holds about 6.51 M in cash with (23.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. | |
| Roughly 68.0% of the company shares are owned by institutional investors |
- Analyzing Kiromic Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kiromic Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Kiromic Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kiromic Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kiromic Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kiromic Biopharma's stock. These opinions can provide insight into Kiromic Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Kiromic Stock
If you are still planning to invest in Kiromic Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kiromic Biopharma's history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |